Skip to main content
Log in

Determination of risk factors for progression in patients with viable tumor at post-chemotherapy lymph node dissection due to disseminated non-seminomatous germ-cell tumors

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

To assess the clinical variables that effect progression in patients with viable tumor after post-chemotherapy lymph node dissection due to disseminated non-seminomatous germ-cell tumors.

Methods

We performed a retrospective analysis of 32 patients with viable tumor after PC-RPLND, operated between 1990 and 2016. Patients were categorized into 2 groups as favorable and non-favorable (intermedia and poor) according to International Germ Cell Consensus Classification (IGCCC). Tumor size was determined as the largest dimension of retroperitoneal mass. Clinical factors and adjuvant chemotherapy were evaluated to impact on recurrence free survival (RFS) and overall survival (OS).

Results

The median age of the patients and follow-up duration were 28.5 (17–51) years and 51.5 (4–253) months, respectively. 5-year RFS and OS were 57.8–66.8%, respectively. On univariate analysis, percentage of viable tumor, IGCCC risk group, primary site, second-line chemotherapy and surgical margin status were significant for RFS (p = 0.034, p = 0.002, p < 0.001, p = 0.011 and p < 0.001, respectively), while IGCCC risk group, second-line chemotherapy and surgical margin status were significant for OS (p = 0.004, p = 0.010 and p < 0.001, respectively). On multivariate analysis, second-line chemotherapy and surgical margin were independent risk factors for RFS (p = 0.016, HR 4.927 95% CI 1.34–18.02 and p < 0.001, OR 9.147 95% CI 2.61–31.98, respectively) and surgical margin status was the only predictor of OS (p = 0.038, HR 3.874 95% CI 1.07–13.69).

Conclusion

Retroperitoneal lymph node dissection with negative surgical margin is essential for patients with viable residual tumor after chemotherapy. Need for second-line chemotherapy shows risk of progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8:1777–1781

    Article  CAS  Google Scholar 

  2. van Dijk MR, Steyerberg EW, Habbema JD (2006) Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer 42:820–826

    Article  Google Scholar 

  3. Spiess PE, Brown GA, Liu P et al (2006) Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107:1483–1490

    Article  Google Scholar 

  4. Hendry WF, Norman AR, Dearnaley DP et al (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94:1668–1676

    Article  Google Scholar 

  5. de Wit R, Stoter G, Kaye SB et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group. J Clin Oncol 15:1837–1843

    Article  Google Scholar 

  6. Albers P, Weissbach L, Krege S et al (2004) Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German testicular cancer study group. J Urol 171:1835–1838

    Article  Google Scholar 

  7. Debono DJ, Heilman DK, Einhorn LH et al (1997) Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455–1464

    Article  CAS  Google Scholar 

  8. Hartmann JT, Candelaria M, Kuczyk MA et al (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33:843–847

    Article  CAS  Google Scholar 

  9. Jacobsen NE, Foster RS, Donohue JP (2007) Retroperitoneal lymph node dissection in testicular cancer. Surg Oncol Clin N Am 16:199–220

    Article  Google Scholar 

  10. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International germ cell cancer collaborative group. J Clin Oncol 15:594–603, 1997

  11. Motzer RJ, Amsterdam A, Prieto V et al (1998) Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 159:133–138

    Article  CAS  Google Scholar 

  12. Fizazi K, Tjulandin S, Salvioni R et al (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy–results from an international study group. J Clin Oncol 19:2647–2657

    Article  CAS  Google Scholar 

  13. Carver BS, Serio AM, Bajorin D et al (2007) Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol 25:5603–5608

    Article  Google Scholar 

  14. Spiess PE, Brown GA, Pisters LL et al (2006) Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 107:1503–1510

    Article  Google Scholar 

  15. Carver BS, Sheinfeld J (2009) Management of post-chemotherapy extra-retroperitoneal residual masses. World J Urol 27:489–492

    Article  Google Scholar 

  16. Spiess PE, Tannir NM, Tu SM et al (2007) Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 110:2700–2708

    Article  Google Scholar 

  17. Fizazi K, Oldenburg J, Dunant A et al (2008) Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 19:259–264

    Article  CAS  Google Scholar 

  18. Sheinfeld J (2002) The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol 20:262–271

    Article  Google Scholar 

  19. Stephenson AJ, Bosl GJ, Motzer RJ et al (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23:2781–2788

    Article  Google Scholar 

  20. Sheinfeld J, Bajorin D (1993) Management of the postchemotherapy residual mass. Urol Clin North Am 20:133–143

    CAS  PubMed  Google Scholar 

  21. Fox EP, Weathers TD, Williams SD et al (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11:1294–1299

    Article  CAS  Google Scholar 

  22. Baniel J, Foster RS, Rowland RG et al (1995) Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 153:976–980

    Article  CAS  Google Scholar 

  23. Baniel J, Sella A (1999) Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol 17:263–267

    Article  CAS  Google Scholar 

Download references

Acknowledgements

No financial support to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mesut Altan.

Ethics declarations

Conflicts of interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Altan, M., Haberal, H.B., Aşçı, A. et al. Determination of risk factors for progression in patients with viable tumor at post-chemotherapy lymph node dissection due to disseminated non-seminomatous germ-cell tumors. Int J Clin Oncol 26, 186–191 (2021). https://doi.org/10.1007/s10147-020-01786-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-020-01786-8

Keywords

Navigation